The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dahms, Sven O ^a,b   Creemers, John W M ^c   Schaub, Yvonne ^a   Bourenkov, Gleb P ^d   Zögg, Thomas ^b,e   Brandstetter, Hans ^b   Than, Manuel E ^a  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b UNIVERSITY OF SALZBURG   (Austria)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989193408     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34303     Document Type: Article

References (41)

1. Thomas, G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3, 753-766 (2002).
2. Artenstein, A. W. & Opal, S. M. Proprotein convertases in health and disease. The New England journal of medicine 365, 2507-2518 (2011).
3. Seidah, N. G, Sadr, M. S, Chretien, M. & Mbikay, M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 288, 21473-21481 (2013).
4. Henrich, S. et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 10, 520-526 (2003).
5. Creemers, J. W, Siezen, R. J, Roebroek, A. J, Ayoubi, T. A, Huylebroeck, D. & Van de Ven, W. J. Modulation of furin-mediated proprotein processing activity by site-directed mutagenesis. J Biol Chem 268, 21826-21834 (1993).
6. Seidah, N. G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11, 367-383 (2012).
7. Basak, A. Inhibitors of proprotein convertases. J Mol Med 83, 844-855 (2005).
8. Coppola, J. M, Bhojani, M. S, Ross, B. D. & Rehemtulla, A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10, 363-370 (2008).
9. Lopez de Cicco, R, Bassi, D. E, Zucker, S, Seidah, N. G. & Klein-Szanto, A. J. Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer research 65, 4162-4171 (2005).
10. Hallenberger, S, Bosch, V, Angliker, H, Shaw, E, Klenk, H. D. & Garten, W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360, 358-361 (1992).
11. Hardes, K. et al. Novel Furin Inhibitors with Potent Anti-infectious Activity. ChemMedChem (2015).
12. Couture, F, D'Anjou, F. & Day, R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomolecular concepts 2, 421-438 (2011).
13. Henrich, S, Lindberg, I, Bode, W. & Than, M. E. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 345, 211-227 (2005).
14. Lu, Y. et al. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. Antiviral Res 120, 89-100 (2015).
15. Dahms, S. O, Hardes, K, Becker, G. L, Steinmetzer, T, Brandstetter, H. & Than, M. E. X-ray Structures of Human Furin in Complex with Competitive Inhibitors. ACS Chem Biol 9, 1113-1118 (2014).
16. Holyoak, T, Kettner, C. A, Petsko, G. A, Fuller, R. S. & Ringe, D. Structural basis for differences in substrate selectivity in Kex2 and furin protein convertases. Biochemistry 43, 2412-2421 (2004).
17. Wheatley, J. L. & Holyoak, T. Differential P1 arginine and lysine recognition in the prototypical proprotein convertase Kex2. Proc Natl Acad Sci USA 104, 6626-6631 (2007).
18. Ganesan, R, Eigenbrot, C. & Kirchhofer, D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J 430, 179-189 (2010).
19. Wu, Y. et al. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc Natl Acad Sci USA 104, 19784-19789 (2007).
20. Farady, C. J, Egea, P. F, Schneider, E. L, Darragh, M. R. & Craik, C. S. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol 380, 351-360 (2008).
21. Tape, C. J. et al. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA 108, 5578-5583 (2011).
22. Ciferri, C. et al. The trimeric serine protease HtrA1 forms a cage-like inhibition complex with an anti-HtrA1 antibody. Biochem J 472, 169-181 (2015).
23. De Meyer, T, Muyldermans, S. & Depicker, A. Nanobody-based products as research and diagnostic tools. Trends in biotechnology 32, 263-270 (2014).
24. Koschubs, T. et al. Allosteric antibody inhibition of human hepsin protease. Biochem J 442, 483-494 (2012).
25. Ganesan, R. et al. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Structure 17, 1614-1624 (2009).
26. Oyen, D, Srinivasan, V, Steyaert, J. & Barlow, J. N. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol 407, 138-148 (2011).
27. Zhu, J. et al. Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J 448, 73-82 (2012).
28. Krissinel, E. & Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 60, 2256-2268 (2004).
29. Decanniere, K, Transue, T. R, Desmyter, A, Maes, D, Muyldermans, S. & Wyns, L. Degenerate interfaces in antigen-antibody complexes. J Mol Biol 313, 473-478 (2001).
30. Scheidig, A. J, Hynes, T. R, Pelletier, L. A, Wells, J. A. & Kossiakoff, A. A. Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities. Protein science: a publication of the Protein Society 6, 1806-1824 (1997).
31. Griessner, A, Zögg, T. & Brandstetter, H. The activation peptide of coagulation factor IX and X serves as a high affinity receptor to cationic ligands. Thrombosis and Haemostasis 110, 620-622 (2013).
32. Sichler, K, Kopetzki, E, Huber, R, Bode, W, Hopfner, K. P. & Brandstetter, H. Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop. J Biol Chem 278, 4121-4126 (2003).
33. Johnson, D. J, Li, W, Adams, T. E. & Huntington, J. A. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. The EMBO journal 25, 2029-2037 (2006).
34. Bradbury, A. R, Sidhu, S, Dubel, S. & McCafferty, J. Beyond natural antibodies: the power of in vitro display technologies. Nature biotechnology 29, 245-254 (2011).
35. Mueller, U. et al. Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin. Journal of synchrotron radiation 19, 442-449 (2012).
36. Kabsch, W. Xds. Acta Crystallogr D Biol Crystallogr 66, 125-132 (2010).
37. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67, 235-242 (2011).
38. McCoy, A. J, Grosse-Kunstleve, R. W, Adams, P. D, Winn, M. D, Storoni, L. C. & Read, R. J. Phaser crystallographic software. Journal of applied crystallography 40, 658-674 (2007).
39. Emsley, P, Lohkamp, B, Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
40. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221 (2010).
41. Turk, D. MAIN software for density averaging, model building, structure refinement and validation. Acta Crystallogr D Biol Crystallogr 69, 1342-1357 (2013).